## nature portfolio

Corresponding author(s):	Trevor A Graham Andrea Sottoriva		
Last updated by author(s):	Aug 5, 2022		

## **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

$\sim$					
C	tっ	ıtı	ıςt	10	·c
- 1	_		<b>.</b>	11	_

For	all statistical ar	alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.	
n/a	Confirmed		
	The exact	sample size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement	
	A stateme	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly	
	The statis Only comm	tical test(s) used AND whether they are one- or two-sided non tests should be described solely by name; describe more complex techniques in the Methods section.	
	A descript	tion of all covariates tested	
	A descript	tion of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons	
	A full deso	cription of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) ition (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)	
	For null h	ypothesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted ses as exact values whenever suitable.	
		ian analysis, information on the choice of priors and Markov chain Monte Carlo settings	
	For hierar	chical and complex designs, identification of the appropriate level for tests and full reporting of outcomes	
	$\square$ Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated		
	'	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.	
So	ftware an	d code	
Policy information about <u>availability of computer code</u>			
Da	ata collection	No software was used for data collection	

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

## Data

Data analysis

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets

https://github.com/T-Heide/MLLPT

- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

https://github.com/sottorivalab/EPICC2021 data analysis

https://github.com/sottorivalab/EPICC2021\_data\_analysis\_RNA

This manuscript is a reanalysis of data in associated manuscript Heide, Househam et al. (2022). The data in that associated manuscript are available on Mendeley (DOI 10.17632/7wx3chtsxx.1) and sequence data have been deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAS00001005230. Additional supplementary information is available on figshare (DOI 10.6084/m9.figshare.c.6122193).

Field	d-speci	fic re	port	ing

	<u> </u>
Please select the o	ne below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
∠ Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of	the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>
Life scier	nces study design
All studies must dis	sclose on these points even when the disclosure is negative.
Sample size	No power calculation was performed prior to starting the study. Post hoc power calculations were performed throughout the study and results interpreted in light of these analyses.
Data exclusions	Various data exclusions were performed on an analysis-by-analysis basis (usually due to available sample numbers with required multi-omics and/or samples per tumour). These are specified in the manuscript at the point that each analysis is described.
Replication	Specific replication on individual samples was not possible due to insufficient material (as described in associated manuscript detailing wet-lab data generation). Repeat sampling of tumours provided a level of psuedo-replication.
Randomization	Randomization was not relevant to this study. The explicit analysis clinical-pathological of covariates, such as mismatch repair status, is reported in the manuscript. Our study was an observational cohort study so randomization was not possible. No differential outcomes were examined so randomization was not needed.
Blinding	Researchers were blinded to clinical-pathological data.
<del> </del>	g for specific materials, systems and methods on from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,
,	on non-authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,

system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Ma	terials & experimental systems	Me	thods
n/a	Involved in the study	n/a	Involved in the study
$\boxtimes$	Antibodies	$\boxtimes$	ChIP-seq
$\boxtimes$	Eukaryotic cell lines	$\boxtimes$	Flow cytometry
$\boxtimes$	Palaeontology and archaeology	$\boxtimes$	MRI-based neuroimaging
$\boxtimes$	Animals and other organisms		
$\boxtimes$	Human research participants		
$\boxtimes$	Clinical data		
$\boxtimes$	Dual use research of concern		